[Home ] [Archive]    
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
Main Menu
Home::
IJRR Information::
For Authors::
For Reviewers::
Subscription::
News & Events::
Web Mail::
::
Search in website

Advanced Search
..
Receive site information
Enter your Email in the following box to receive the site news and information.
..
ISSN
Hard Copy 2322-3243
Online 2345-4229
..
Online Submission
Now you can send your articles to IJRR office using the article submission system.
..

AWT IMAGE

AWT IMAGE

:: Search published articles ::
Showing 1 results for Levonorgestrel Intrauterine Contraceptive System

P. Lian, H. Xu, S. Liu, M.d., H. Qian,
Volume 23, Issue 2 (5-2025)
Abstract

Background: Exploring the efficacy of levonorgestrel intrauterine contraceptive system combined with hysteroscopic resection for the treatment of early and highly differentiated endometrial cancer in young patients and its impact on reproductive function. Materials and Methods: According to the grouping method, the patients were divided into a single hysteroscopy group and a combined progesterone group, with 77 patients in each group. Among them, the single hysteroscopy group received hysteroscopic resection surgery, while the combined progesterone group received levonorgestrel intrauterine contraceptive system treatment on hysteroscopic resection surgery beside radiation. Results: After treatment, endometrial thickness, uterine volume and myoma volume were lower in the combined treatment group than in the intrauterine sustained release group (P<0.05); after treatment, estradiol, FSH and progesterone levels were lower in the combined treatment group compared with the intrauterine sustained release group (P<0.05); after treatment, Hb and VEGF levels were lower in the combined treatment group compared with the intrauterine sustained release group (P < 0.05); after treatment, compared with the intrauterine sustained release group, Hb and VEGF levels were lower in the combined treatment group (P<0.05);Compared with the intrauterine sustained release group, the dysmenorrhea score and CA125 expression level in the combined treatment group were lower (P<0.05); compared with the intrauterine sustained release group, the effective rate of the combined treatment group was higher (P<0.05). Conclusion: The application of mifepristone combined with levonorgestrel intrauterine sustained release system in the treatment of patients with uterine fibroids can effectively improve the symptoms of patients, alleviate clinical symptoms, alleviate dysmenorrhea, effectively inhibit the further development of the disease, reduce the expression level of CA125, improve the prognosis of patients, and have a significant therapeutic effect.


Page 1 from 1     

International Journal of Radiation Research
Persian site map - English site map - Created in 0.07 seconds with 37 queries by YEKTAWEB 4714